Take our Addiction Test

Find a therapist to overcome addiction

Research on synthetic 5-MeO-DMT has advanced from early observational studies to positive clinical trials.

Scientists have moved from natural toad secretions to standardized 5-MeO-DMT pharmaceutical formulations.

Major questions remain regarding durability, optimal dosing, placebo effects, and long-term safety.

Earlier this year, I wrote about one of psychiatry's most unusual drug-development stories: a psychedelic compound first identified in the defensive secretions of the Sonoran Desert toad that has now entered the realm of randomized clinical trials for severe depression. The field has advanced dramatically beyond the early period when the compound was known primarily through recreational use and colorful names such as Bufo, Sapito, "the toad," and even "the Joe Rogan psychedelic." Today's scientific story, however, has surprisingly little to do with the toad itself.

Many medicines began with unexpected observations in nature. Aspirin originated from willow bark. Penicillin emerged from mold. Psilocybin was isolated from naturally occurring mushrooms; GLP-1 receptor agonists owe part of their development to studies of Gila monster saliva. In each case, scientists did not simply use the natural source—they identified the active molecule, developed standardized pharmaceutical formulations, and rigorously tested them. The story of 5-MeO-DMT appears to be following that same path.

The first randomized, placebo-controlled Phase 2b trial of inhaled synthetic 5-MeO-DMT has now reported robust antidepressant effects in patients with treatment-resistant depression, moving the field well beyond the small open-label studies that initially generated excitement. Cubala and colleagues’ study is now the landmark clinical study in the field. Participants experienced large reductions in depression severity, remission rates approaching 60 percent after a single treatment day, and no serious adverse events during the blinded phase. Psychiatric researchers have searched for faster and more effective antidepressants for decades. These findings represent an important milestone.

If ongoing studies continue to confirm clinical benefit, psychiatry may be looking at a carefully supervised intervention measured in minutes rather than months.

The momentum became even more apparent when Eli Lilly disclosed plans to acquire AtaiBeckley for up to $3.8 billion, largely to obtain BPL-003, an intranasal formulation of synthetic 5-MeO-DMT. Of course, a multibillion-dollar acquisition does not guarantee FDA approval. But when one of the world's largest neuroscience companies believes the science has matured enough to justify a major investment, attention is paid. The attraction is not simply to acquire........

© Psychology Today